高价人参皂苷食品暗示抗癌功效，富生制药被指虚假宣传

Core Viewpoint - The company Dalian Fusheng Pharmaceutical is under scrutiny for misleading advertising of its product "Fuli Doctor Ginsenoside Rg3," which is marketed as having anti-tumor effects but is actually a solid beverage and not a drug [1][2][6]. Product Description - The product "Fuli Doctor Ginsenoside Rg3" is sold at a price of 1780 yuan per box and is classified as a solid beverage, containing mainly ginseng roots aged five years or less [1][2]. - The product's composition includes ginsenosides Rg3 and Rg5, with specific amounts stated, but it lacks any unique medicinal ingredients [2][3]. Marketing and Promotion Tactics - The company employs various promotional strategies, including showcasing research achievements and using AI to suggest potential health benefits, which may mislead consumers into believing the product has anti-cancer properties [3][9][14]. - The marketing materials frequently reference the product's association with a drug called "Can Yi Capsule," which has been approved for cancer treatment, creating a misleading connection between the food product and pharmaceutical efficacy [6][26]. Legal and Regulatory Concerns - The promotional practices may violate the Anti-Unfair Competition Law and the Price Law of the People's Republic of China, as they could be seen as misleading consumers regarding the product's capabilities and pricing [6][7][8][26]. - Legal experts indicate that the company's actions could be classified as "confusion behavior," potentially leading to penalties if deemed unlawful [6][26]. Scientific Evidence and Expert Opinions - Experts note that while there is some evidence suggesting ginsenoside Rg3 may have anti-cancer properties, the clinical evidence supporting its efficacy is insufficient, with most studies being small-scale and lacking rigorous design [21][22]. - The product's marketing may lead consumers to mistakenly believe it can replace conventional cancer treatments, which poses significant health risks [25][26].